```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  May 12   EXTEND option available in structure searching
 NEWS  4  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS  6  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28   Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28   ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                   and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS 10  Jul 30   BEILSTEIN on STN workshop to be held August 24 in conjunction
                   with the 228th ACS National Meeting
 NEWS 11  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS 12  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS 13  AUG 02   STN User Update to be held August 22 in conjunction with the
                   228th ACS National Meeting
 NEWS 14  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004

=> file medline, uspatful, dgene, embase, wpids, fsta,
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    0.42        0.42

FILE 'MEDLINE' ENTERED AT 12:05:52 ON 03 AUG 2004

FILE 'USPATFULL' ENTERED AT 12:05:52 ON 03 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:05:52 ON 03 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s annexin
L1       12293 ANNEXIN

=> s MDR or multidrug resistance or multi-drug resistance
   5 FILES SEARCHED...
L2       40790 MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE

=> s l2 and inhibition
L3        6951 L2 AND INHIBITION

=> s l3 and Annexin I
L4          10 L3 AND ANNEXIN I

=> d l4 ti abs ibib tot

L4   ANSWER 1 OF 10  USPATFULL on STN
TI     Lectin compositions and methods for modulating an immune response to an
       antigen
AB     The present invention provides a fusion polypeptide which can bind to a
       cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand
       for a cell surface polypeptide, as well as a vector comprising a nucleic
       acid encoding for such a fusion polypeptide, and a host cell comprising
       such nucleic acid. The present invention also provides a composition
       comprising an antigen bearing target and such a fusion polypeptide, as
       well as a composition comprising a virus or a cell and such a fusion
       polypeptide. The present invention further relates to a method of
       modulating an immune response in an animal using such compositions.

ACCESSION NUMBER:        2004:185003  USPATFULL
TITLE:                   Lectin compositions and methods for modulating an
                         immune response to an antigen
INVENTOR(S):             Segal, Andrew H., Boston, MA, UNITED STATES
                         Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S):      Genitrix,LLC (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004142889      A1   20040722
APPLICATION INFO.:       US 2003-666898     A1   20030919  (10)
RELATED APPLN. INFO.:    Division of Ser. No. US 2003-645000, filed on 20 Aug
                         2003, PENDING

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2002-404823P    20020820 (60)
```

	US 2003-487407P 20030715 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS:	69
EXEMPLARY CLAIM:	1
LINE COUNT:	7754

L4 ANSWER 2 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:165307 USPATFULL		
TITLE:	Lectin compositions and methods for modulating an immune response to an antigen		
INVENTOR(S):	Segal, Andrew H., Boston, MA, UNITED STATES Young, Elihu, Sharon, MA, UNITED STATES		
PATENT ASSIGNEE(S):	Genitrix, LLC (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126793	A1	20040701
APPLICATION INFO.:	US 2003-666885	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)	
	US 2003-487407P	20030715 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199		
NUMBER OF CLAIMS:	147		
EXEMPLARY CLAIM:	1		
LINE COUNT:	28979		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 10 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:164872 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126357	A1	20040701
APPLICATION INFO.:	US 2003-666886	A1	20030919 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 39007
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 10 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:159413 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122217	A1	20040624
APPLICATION INFO.:	US 2003-666871	A1	20030919 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 68

EXEMPLARY CLAIM: 1
LINE COUNT: 7880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 10 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:120097 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004091503	A1	20040513	
APPLICATION INFO.:	US 2003-645000	A1	20030820	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-404823P	20020820	(60)
	US 2003-487407P	20030715	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 78
EXEMPLARY CLAIM: 1
LINE COUNT: 7933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 10 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:51725 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew, Boston, MA, UNITED STATES
Young, Eli, Sharon, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004039156	A1	20040226	
APPLICATION INFO.:	US 2002-224661	A1	20020820	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 7091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 10 USPATFULL on STN
TI Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
AB A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for diagnosing a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:12636 USPATFULL
TITLE: Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
INVENTOR(S): Khan, Javed, Derwood, MD, UNITED STATES
Ringner, Markus, Lund, SWEDEN
Peterson, Carsten, Lund, SWEDEN
Meltzer, Paul, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009154	A1	20040115
APPLICATION INFO.:	US 2002-159563	A1	20020531 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-133937, filed on 25 Apr 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCHANT & GOULD PC, 3200 IDS CENTER, 80 SOUTH EIGHTH STREET, MINNEAPOLIS, MN, 55402-0903
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 3943
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 10 USPATFULL on STN
TI Expression profile of prostate cancer
AB The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250950 USPATFULL
TITLE: Expression profile of prostate cancer
INVENTOR(S): Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES
Rubin, Mark A., Ann Arbor, MI, UNITED STATES
Sreekumar, Arun, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175736	A1	20030918
APPLICATION INFO.:	US 2002-210120	A1	20020801 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309581P	20010802 (60)
	US 2001-334468P	20011115 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 129 Drawing Page(s)
LINE COUNT: 11938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 10 USPATFULL on STN

TI Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction

AB The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIYFKLVTM.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFLKVLKLNKT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with Annexin. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:258778 USPATFULL
TITLE: Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
INVENTOR(S): Georges, Elias, Laval, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109

NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 10 USPATFULL on STN
TI Taxol resistance associated gene
AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:64018 USPATFULL
TITLE: Taxol resistance associated gene
INVENTOR(S): Seiden, Michael V., Wayland, MA, United States
Duan, Zhenfeng, Cambridge, MA, United States
Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362321	B1	20020326
APPLICATION INFO.:	US 1999-277303		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Harris, Alana M.
LEGAL REPRESENTATIVE: Fish & Richardson, P.C.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 12:05:52 ON 03 AUG 2004
L1 12293 S ANNEXIN
L2 40790 S MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE
L3 6951 S L2 AND INHIBITION
L4 10 S L3 AND ANNEXIN I

=> s l1 with MDR
MISSING OPERATOR L1 WITH
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s annexin with MDR
L5 1 ANNEXIN WITH MDR

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Modulating or assessing multidrug resistance related to annexin proteins.
AN 1999-337419 [28] WPIDS
AB WO 9921980 A UPAB: 19990719
NOVELTY - Isolated nucleic acid (I) encoding an annexin family member (II), i.e. a member of the MDR (multidrug resistance) gene family, for assessing or modulating MDR in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect **annexin**-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;

(7) pharmaceutical composition for reducing MDR comprising **annexin**-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing multidrug resistance related to annexin proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9896174	A	Based on	WO 9921980
EP 1025225	A1	Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> s l1 and drug resistance
L6 434 L1 AND DRUG RESISTANCE

=> s l6 and inhibit
=> s l6 and inhibit?
L7 351 L6 AND INHIBIT?

=> s l7 and (Annexin I)?
MISSING OPERATOR I)?
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l7 and (annexin I)
L8 12 L7 AND (ANNEXIN I)

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 12 MEDLINE on STN
TI Dexamethasone-induced cytotoxic activity and **drug resistance** effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1.
AB We have examined the effects that dexamethasone (DEX), alone or in combination with doxorubicin (DOX), cisplatin (CDDP), or etoposide (VP-16), exerts on the growth of the androgen-independent prostate cancer PC-3 cells. DEX exhibited only a limited cytotoxicity (growth **inhibition** of about 28% or 20% after 24 or 72 h of exposure, respectively, in the range of DEX 10-100 nM) and did not induce apoptosis in the cells. This cytotoxicity of DEX was mimicked by an active peptide (peptide Ac2-26) drawn from the human lipocortin 1 N-terminus region and abrogated by an antibody to human lipocortin 1. Two **inhibitors** of arachidonic acid metabolism, tenidap and indomethacin, also caused cytotoxicity. The cytotoxic effects of DEX in combination with DOX, CDDP, or VP-16 were antagonistic when the steroid was administered 3 h before or simultaneously with the drugs. Other schedule-dependency experiments further clarified that, at least in the case of the combination with DOX, it is the steroid that desensitizes the cells to the drug. When peptide Ac2-26, tenidap, or indomethacin were tested in combination with DOX, antagonism was also observed. DEX treatment neither modified the ability of the cells to accumulate DOX nor changed their weak expression of P-glycoprotein. PC-3 cells also produce IL-6, which autocrinally stimulates their growth, and whose gene expression may be reduced by glucocorticoids. In the present experiments DEX only slightly decreased

the production and secretion of IL-6 by the cells. The present findings suggest that the slight cytotoxic activity and the **drug resistance** effects of DEX on PC-3 cells are mediated by induction of lipocortin 1 and **inhibition** of arachidonic acid metabolism, with no relationship to downregulation of IL-6 levels. These findings indicate also that the combination of DEX with conventional chemotherapeutic agents may result in antagonistic antitumor effects.

ACCESSION NUMBER: 1999018867 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9802059
TITLE: Dexamethasone-induced cytotoxic activity and **drug resistance** effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1.
AUTHOR: Carollo M; Parente L; D'Alessandro N
CORPORATE SOURCE: Institute of Pharmacology, Faculty of Medicine, University of Palermo, Italy.
SOURCE: Oncology research, (1998) 10 (5) 245-54.
Journal code: 9208097. ISSN: 0965-0407.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199901
ENTRY DATE: Entered STN: 19990115
Last Updated on STN: 19990115
Entered Medline: 19990104

L8 ANSWER 2 OF 12 MEDLINE on STN
TI Possible mechanisms of glucocorticoid--unresponsive pyrexia. Defect in lipocortin 1?.
AB Glucocorticoids have a strong anti-inflammatory action, and are indispensable in the treatment of inflammatory diseases. We had a patient with the Weber-Christian disease having an intractable high fever that did not respond to even a high-dose glucocorticoid therapy, but was responsive to a nonsteroidal antiinflammatory drug. To elucidate possible mechanisms of the glucocorticoid-unresponsive fever, we have investigated the in vitro production of two eicosanoids, prostaglandin (PG)E2 and leukotriene (LT)B4, from the peripheral blood polymorphonuclear leukocytes after stimulation by ionophore A23187. The patient's leukocytes produced much larger amount of PGE2, but the same amount of LTB4, as did those of two control groups. More interestingly, the production of eicosanoids was **inhibited** by dexamethasone less in the patients than in the controls. Indomethacin suppressed the production of PGE2 both in the patients and in the controls. These results might be relevant in the glucocorticoid-unresponsive pyrexia.

ACCESSION NUMBER: 97089287 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8935195
TITLE: Possible mechanisms of glucocorticoid--unresponsive pyrexia. Defect in lipocortin 1?.
AUTHOR: Akama H; Tanaka H; Kawai S
CORPORATE SOURCE: Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
SOURCE: Materia medica Polona. Polish journal of medicine and pharmacy, (1995 Apr-Jun) 27 (2) 75-8.
Journal code: 0236526. ISSN: 0025-5246.
PUB. COUNTRY: Poland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199612
ENTRY DATE: Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961223

L8 ANSWER 3 OF 12 MEDLINE on STN

TI High-level expression of human lipocortin I in the fission yeast Schizosaccharomyces pombe using a novel expression vector.

AB We have developed a novel expression system that allows the fission yeast, Schizosaccharomyces pombe, to be used for the efficient overproduction of heterologous proteins. As an example of the utility of this system, human lipocortin I was expressed to 50 percent of soluble protein, and 150 mg of highly purified material was obtained from 10 grams of wet cell paste. Expression of lipocortin I was driven by the human cytomegalovirus (hCMV) promoter in a vector that also contains a neomycin resistance gene (neo) under the control of the SV40 early promoter, permitting selection for increasing copy-number with increasing concentrations of the antibiotic G418. The purified protein was equivalent to its native counterpart with respect to antigenicity and biochemical properties such as phospholipase A2 **inhibition**, actin binding and N-terminal acetylation. We have also used this system to produce comparable amounts of other proteins including rat arginase, rat NDP-kinase and human interleukin-6.

ACCESSION NUMBER: 94226791 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7764687
TITLE: High-level expression of human lipocortin I in the fission yeast Schizosaccharomyces pombe using a novel expression vector.
AUTHOR: Giga-Hama Y; Tohda H; Okada H; Owada M K; Okayama H; Kumagai H
CORPORATE SOURCE: Research Center, Asahi Glass Co. Ltd, Kanagawa, Japan.
SOURCE: Bio/technology (Nature Publishing Company), (1994 Apr) 12 (4) 400-4.
Journal code: 8309273. ISSN: 0733-222X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Biotechnology
ENTRY MONTH: 199406
ENTRY DATE: Entered STN: 19950809
Last Updated on STN: 19950809
Entered Medline: 19940609

L8 ANSWER 4 OF 12 USPATFULL on STN

TI Molecular toxicology modeling

AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:94708 USPATFULL
TITLE: Molecular toxicology modeling
INVENTOR(S): Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072160	A1	20040415	
APPLICATION INFO.:	US 2002-152319	A1	20020522	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-292335P	20010522	(60)

	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)
	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)
	US 2001-315047P	20010828 (60)
	US 2001-324928P	20010927 (60)
	US 2001-330867P	20011101 (60)
	US 2001-330462P	20011022 (60)
	US 2001-331805P	20011121 (60)
	US 2001-336144P	20011206 (60)
	US 2001-340873P	20011219 (60)
	US 2002-357843P	20020221 (60)
	US 2002-357842P	20020221 (60)
	US 2002-357844P	20020221 (60)
	US 2002-364134P	20020315 (60)
	US 2002-370206P	20020408 (60)
	US 2002-370247P	20020408 (60)
	US 2002-370144P	20020408 (60)
	US 2002-371679P	20020412 (60)
	US 2002-372794P	20020417 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
LINE COUNT:	27909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 12 USPATFULL on STN

TI Expression profile of prostate cancer

AB The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:250950 USPATFULL			
TITLE:	Expression profile of prostate cancer			
INVENTOR(S):	Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES Rubin, Mark A., Ann Arbor, MI, UNITED STATES Sreekumar, Arun, Ann Arbor, MI, UNITED STATES			
PATENT ASSIGNEE(S):	The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003175736	A1	20030918	
APPLICATION INFO.:	US 2002-210120	A1	20020801	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-309581P		20010802	(60)
	US 2001-334468P		20011115	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105			
NUMBER OF CLAIMS:	101			
EXEMPLARY CLAIM:	1			

NUMBER OF DRAWINGS: 129 Drawing Page(s)
LINE COUNT: 11938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 12 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:194491 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134302	A1	20030717
APPLICATION INFO.:	US 2002-210985	A1	20020801 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 9810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 12 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:106252 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES

Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073163	A1	20030417
APPLICATION INFO.:	US 2001-3021	A1	20011114 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 9813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 12 USPATFULL on STN
TI Early stage multipotential stem cells in colonies of bone marrow stromal cells
AB Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:301221 USPATFULL
TITLE: Early stage multipotential stem cells in colonies of bone marrow stromal cells
INVENTOR(S): Prockop, Darwin J., New Orleans, LA, UNITED STATES
Colter, David C., Philadelphia, PA, UNITED STATES
Sekiya, Ichiro, New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168765	A1	20021114
APPLICATION INFO.:	US 2001-816182	A1	20010323 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 Market Street, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 12 USPATFULL on STN
TI Protein-protein interactions and methods for identifying interacting

proteins and the amino acid sequence at the site of interaction

AB The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIYFKLVTM.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFLKVLKLNKT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with **Annexin**. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:258778 USPATFULL		
TITLE:	Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction		
INVENTOR(S):	Georges, Elias, Laval, CANADA		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Page(s)		
LINE COUNT:	2044		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 12 USPATFULL on STN

TI Nucleic acids, proteins and antibodies

AB This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying

agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for **inhibiting** the production and/or function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:99407 USPATFULL
TITLE:	Nucleic acids, proteins and antibodies
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052308	A1	20020502
APPLICATION INFO.:	US 2001-925301	A1	20010810 (9)

RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-124270P	19990312 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
LINE COUNT:	30577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 12 USPATFULL on STN

TI Taxol resistance associated gene

AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:64018 USPATFULL
TITLE:	Taxol resistance associated gene
INVENTOR(S):	Seiden, Michael V., Wayland, MA, United States Duan, Zhenfeng, Cambridge, MA, United States Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S):	The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6362321	B1	20020326
APPLICATION INFO.:	US 1999-277303		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Caputa, Anthony C.
ASSISTANT EXAMINER:	Harris, Alana M.
LEGAL REPRESENTATIVE:	Fish & Richardson, P.C.
NUMBER OF CLAIMS:	15
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:	1036

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 12 USPATFULL on STN
TI Human single nucleotide polymorphisms
AB The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from genes including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:55155 USPATFULL		
TITLE:	Human single nucleotide polymorphisms		
INVENTOR(S):	Cargill, Michele, Gaithersburg, MD, UNITED STATES Ireland, James S., Gaithersburg, MD, UNITED STATES Lander, Eric S., Cambridge, MA, UNITED STATES		
PATENT ASSIGNEE(S):	Whitehead Institute for Biomedical Research, Cambridge, MA, UNITED STATES (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032319	A1	20020314
APPLICATION INFO.:	US 2001-801274	A1	20010307 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-187510P		20000307 (60)
	US 2000-206129P		20000522 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HAMILTON BROOK SMITH AND REYNOLDS, P.C., TWO MILITIA DR, LEXINGTON, MA, 02421-4799		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8981		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:04:37 ON 03 AUG 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 12:05:52 ON 03 AUG 2004

L1 12293 S ANNEXIN
L2 40790 S MDR OR MULTIDRUG RESISTANCE OR MULTI-DRUG RESISTANCE
L3 6951 S L2 AND INHIBITION
L4 10 S L3 AND ANNEXIN I
L5 1 S ANNEXIN WITH MDR
L6 434 S L1 AND DRUG RESISTANCE
L7 351 S L6 AND INHIBIT?
L8 12 S L7 AND (ANNEXIN I)

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.66	70.08

FILE 'MEDLINE' ENTERED AT 12:17:25 ON 03 AUG 2004

FILE LAST UPDATED: 1 AUG 2004 (20040801/UP). FILE COVERS 1951 TO DATE.

```
 On February 29, 2004, the 2004 MeSH terms were loaded.  See HELP RLOAD
 for details. OLDMEDLINE now back to 1951.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2004 vocabulary.  See http://www.nlm.nih.gov/mesh/ and
 http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a
 description of changes.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s P-40+NT/CT
'P-40' NOT IN RELATIONSHIP FILE
RELATIONSHIP CODE 'NT' IGNORED
L9            0 P-40+NT/CT  (1 TERM)

=> e "P-40"
E1            1     OZZT/BI
E2      2307533     P/BI
E3            0 --> P-40/BI
E4         2984     P0/BI
E5            4     P00/BI
E6            1     P000/BI
E7            1     P00004/BI
E8            1     P00037/BI
E9            3     P0004/BI
E10           5     P0006/BI
E11           8     P001/BI
E12           1     P00126/BI

=> e P-40/CT
E#   FREQUENCY     AT      TERM
--   ---------     --      ----
E1            0      1     P-286/CT
E2            0      2     P-286 (CONTRAST MEDIA)/CT
E3            0        --> P-40/CT
E4            0      1     P-450/CT
E5            0      2     P-450 4A, CYTOCHROME/CT
E6            0      2     P-450 CYP2D6, CYTOCHROME/CT
E7            0      2     P-450 CYP4A, CYTOCHROME/CT
E8            0      2     P-450 IVA, CYTOCHROME/CT
E9            0      2     P-450 OXIDASE, CYTOCHROME/CT
E10           0      1     P-450-CAM/CT
E11           0      1     P-450-DEPENDENT/CT
E12           0      2     P-450-DEPENDENT O-DEALKYLASE, CYTOCHROME/CT

=> s "p-40"
       2307533 "P"
        397211 "40"
L10       1433 "P-40"
                 ("P"(W)"40")

=> s l10 and l1
L11           4 L10 AND L1

=> d l11 ti abs ibib tot

L11  ANSWER 1 OF 4     MEDLINE on STN
TI   Annexin-I expression modulates drug resistance in tumor cells.
AB   The use of anti-cancer chemotherapy often leads to the rise of
     multidrug-resistant (MDR) tumors.  We have previously reported the
     overexpression of a 40kDa protein (P-40) in several
     MDR tumor cell lines.  In this report we describe the cloning of a 1.4kb
     cDNA with an open reading frame of 344 amino acids that encodes the
```

P-40 protein. Analysis of the **P-40** amino acid sequence showed it is identical to the human **annexin** I (Anx-I) protein. The identity of the isolated **P-40** cDNA as Anx-I was confirmed by the specific binding of IPM96 mAb to a 40kDa protein following the in vitro expression of **P-40** full-length cDNA. Northern blot analysis of total RNA from drug-sensitive and -resistant cells revealed an increase in **P-40** (or Anx-I) mRNA in drug-resistant cells relative to drug-sensitive cells. Transfection of Anx-I cDNA into drug-sensitive MCF-7 cells was carried out without further drug selection and showed 2- to 5-fold increase in resistance of transfected cells to adriamycin, melphalan, and etoposide. Conversely, transfection of reverse Anx-I cDNA into SKOV-3 cells decreased the expression of Anx-I without affecting the expression of other members of the **annexin** family and showed a 3- to 8-fold increase in sensitivity to these drugs. Of interest was the correlation between the presence of Anx-I and MDR in MDA-MB-231 cells when compared to MCF-7 cells. MDA-MB-231 cells show 3- to 20-fold increase in resistance to adriamycin, melphalan, and etoposide in the absence of detectable levels of P-glycoprotein (P-gp1), the multidrug resistance protein (MRP1) or the breast cancer resistance protein (BCRP). Taken together, these results provide the first direct evidence for the role of Anx-I in MDR of tumor cells.

ACCESSION NUMBER: 2004033900 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14733945
TITLE: **Annexin**-I expression modulates drug resistance in tumor cells.
AUTHOR: Wang Ying; Serfass Lucile; Roy Marie Odile; Wong Judy; Bonneau Anne Marie; Georges Elias
CORPORATE SOURCE: Institute of Parasitology, McGill University, Macdonald Campus, Ste-Anne de Bellevue, Que., Canada.
SOURCE: Biochemical and biophysical research communications, (2004 Feb 6) 314 (2) 565-70.
Journal code: 0372516. ISSN: 0006-291X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 20040122
Last Updated on STN: 20040306
Entered Medline: 20040305

L11 ANSWER 2 OF 4 MEDLINE on STN
TI GTP-induced membrane binding and ion channel activity of **annexin** VI: is **annexin** VI a GTP biosensor?.
AB **Annexin** VI (AnxVI) formed ion channels in planar lipid bilayers that were induced by the addition of millimolar guanosine 5'-triphosphate (GTP) at pH 7.4 and that were not accompanied by a penetration of the protein into the membrane hydrophobic region. GTP-influenced interactions of AnxVI with Ca2+/liposomes produced small structural alterations as revealed by circular dichroism and infrared spectroscopies. Guanosine 5'-3-O-(thio)-triphosphate (GTPgammaS) binding to AnxVI, promoted by the photorelease of GTPgammaS from GTPgammaS[1-(4,5-dimethoxy-2-nitrophenyl)-ethyl] (caged-GTPgammaS), affected three to four amino acid residues of AnxVI in the presence of Ca2+/liposomes, while about eight or nine amino acid residues were altered in their absence. This suggested that the nucleotide-binding site overlapped the lipid-binding domain of AnxVI. The binding of the fluorescent GTP analog, 2'-(or 3')-O-(2,4,6-trinitrophenyl)guanosine 5'-triphosphate (TNP-GTP) to AnxVI was optimal in the presence of Ca2+/liposomes, with a dissociation constant (K(d)) of 1 microM and stoichiometry of 1. TNP-GTP promoted fluorescence resonance energy transfer from tryptophan residues to the nucleotide. Ion conductance and fluorescence measurements of the C- and N-terminal fragments of AnxVI indicated distinct GTP-binding properties, suggesting

that the existence of the GTP-induced ion channel activity of AnxVI is associated with the flexibility of the two halves of the protein. Such structural flexibility could contribute to a molecular mechanism of AnxVI acting as a GTP biosensor.

ACCESSION NUMBER: 2002246408 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11964259
TITLE: GTP-induced membrane binding and ion channel activity of **annexin** VI: is **annexin** VI a GTP biosensor?.
AUTHOR: Kirilenko Aneta; Golczak Marcin; Pikula Slawomir; Buchet Rene; Bandorowicz-Pikula Joanna
CORPORATE SOURCE: Department of Cellular Biochemistry, Nencki Institute of Experimental Biology, 02-093 Warsaw, Poland.
SOURCE: Biophysical journal, (2002 May) 82 (5) 2737-45. Journal code: 0370626. ISSN: 0006-3495.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020503
Last Updated on STN: 20020925
Entered Medline: 20020924

L11 ANSWER 3 OF 4 MEDLINE on STN
TI Annexins V and XII insert into bilayers at mildly acidic pH and form ion channels.
AB The functional hallmark of annexins is the ability to bind to the surface of phospholipid membranes in a reversible, Ca(2+)-dependent manner. We now report that human **annexin** V and hydra **annexin** XII reversibly bound to phospholipid vesicles in the absence of Ca(2+) at low pH; half-maximal vesicle association occurred at pH 5.3 and 5. 8, respectively. The following biochemical data support the hypothesis that these annexins insert into bilayers at mildly acidic pH. First, a photoactivatable reagent (3-trifluoromethyl)-3-(m-[(125)I]iodophenyl)diazirine) which selectively labels proteins exposed to the hydrophobic domain of bilayers reacted with these annexins at pH 5.0 and below but not at neutral pH. Second, in a Triton X-114 partitioning assay, annexins V and XII act as integral membrane proteins at low pH and as hydrophilic proteins at neutral pH; in the presence of phospholipids half-maximal partitioning into detergent occurred at pH approximately 5.0. Finally, **annexin** V or XII formed single channels in phospholipid bilayers at low pH but not at neutral pH. A model is discussed in which the concentrations of H(+) and Ca(2+) regulate the reversible conversion of three forms of annexins-soluble, peripheral membrane, and transmembrane.

ACCESSION NUMBER: 2000181674 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10715122
TITLE: Annexins V and XII insert into bilayers at mildly acidic pH and form ion channels.
AUTHOR: Isas J M; Cartailler J P; Sokolov Y; Patel D R; Langen R; Luecke H; Hall J E; Haigler H T
CORPORATE SOURCE: Department of Physiology and Biophysics, University of California, Irvine, California 92697, USA.
CONTRACT NUMBER: GM55651 (NIGMS)
GM56445 (NIGMS)
GM57998 (NIGMS)
SOURCE: Biochemistry, (2000 Mar 21) 39 (11) 3015-22. Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200004

ENTRY DATE: Entered STN: 20000427
Last Updated on STN: 20000427
Entered Medline: 20000414

L11 ANSWER 4 OF 4 MEDLINE on STN
TI Anomalous changes in forward scatter of lymphocytes with loosely packed membranes.
AB BACKGROUND: Forward scatter (FSC) is generally associated with cell size and has been suggested as a way to differentiate apoptotic from viable cells. Among spleen cells cultured for 48 h, a population of cells (population B) was found to have decreased forward and increased side scatter relative to freshly purified cells (population A). Interestingly, population B was not present early in analysis; this report explores the change in FSC of population B. METHODS: Using a Coulter (Hialeah, FL) Epics Elite ESP flow cytometer, changes in forward scatter and lipid packing of spleen cells were measured. RESULTS: Over time, the FSC of unfixed cells in population B increased from that of the debris field, to reach a stable value by 30 sec (population A's FSC remained constant). When fixed, populations A and B exhibited constant FSC. Population B cells displayed altered lipid packing as reported by MC540, and the FSC changes were mimicked by Nonidet **P-40** treatment of freshly purified spleen cells. CONCLUSIONS: Data emphasize the importance of delaying measurements on unfixed cells until FSC readings have stabilized, and suggest that flow cytometry may be a useful tool in studying lipid packing.

ACCESSION NUMBER: 1999451075 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10520198
TITLE: Anomalous changes in forward scatter of lymphocytes with loosely packed membranes.
AUTHOR: Scherer J M; Stillwell W; Jenski L J
CORPORATE SOURCE: Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana.. jscherer@iupui.edu
CONTRACT NUMBER: R01CA57212 (NCI)
SOURCE: Cytometry : journal of the Society for Analytical Cytology, (1999 Nov 1) 37 (3) 184-90.
Journal code: 8102328. ISSN: 0196-4763.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199911
ENTRY DATE: Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991119

=> e wang, Y/au
E1 4 WANG ZUOYUAN/AU
E2 2 WANG ZUYI/AU
E3 0 --> WANG, Y/AU
E4 1 WANG1 Y/AU
E5 1 WANGA D B/AU
E6 1 WANGA I/AU
E7 2 WANGA J/AU
E8 1 WANGA K C/AU
E9 1 WANGA K K/AU
E10 1 WANGA MIKE A/AU
E11 1 WANGA O/AU
E12 1 WANGA X J/AU

=> e georges, E/au
E1 3 GEORGES W/AU

```
E2            3      GEORGES Y/AU
E3            0 --> GEORGES, E/AU
E4            1      GEORGESC M/AU
E5            1      GEORGESCAUD D/AU
E6           23      GEORGESCAULD D/AU
E7            1      GEORGESCAULT D/AU
E8            8      GEORGESCO A/AU
E9            1      GEORGESCO B/AU
E10          14      GEORGESCO C/AU
E11           2      GEORGESCO D/AU
E12           1      GEORGESCO E/AU

=> file scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.44      75.52

FILE 'SCISEARCH' ENTERED AT 12:24:40 ON 03 AUG 2004
COPYRIGHT 2004 THOMSON ISI

FILE COVERS 1974 TO 29 Jul 2004 (20040729/ED)

=> e Georges, E/au
E1            2      GEORGES Y/AU
E2            1      GEORGES YATES E/AU
E3            0 --> GEORGES, E/AU
E4            5      GEORGESC C/AU
E5            4      GEORGESC D/AU
E6            2      GEORGESC II/AU
E7            2      GEORGESC M/AU
E8            2      GEORGESC S/AU
E9            1      GEORGESC V/AU
E10           1      GEORGESCAUD D/AU
E11          29      GEORGESCAULD D/AU
E12           1      GEORGESCAULT D/AU

=> e wang, y/au
E1          336      WANG Z Z/AU
E2            2      WANG ZHU Y R/AU
E3            0 --> WANG, Y/AU
E4            1      WANGA M A/AU
E5            1      WANGA O/AU
E6            1      WANGA T/AU
E7            1      WANGA X S/AU
E8            1      WANGA Z Z/AU
E9            9      WANGAARD C/AU
E10           2      WANGAARD C H/AU
E11           2      WANGAARD D B/AU
E12           4      WANGAARD F F/AU

=> file medline, uspatful, dgene, embase, wpids, fsta,  wpids, japio, biobusiness,
jicst,biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.12      79.64

FILE 'MEDLINE' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'USPATFULL' ENTERED AT 12:25:47 ON 03 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:25:47 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT
```

FILE 'EMBASE' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'WPIDS' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'FSTA' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'JAPIO' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'BIOBUSINESS' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'JICST-EPLUS' ENTERED AT 12:25:47 ON 03 AUG 2004

FILE 'BIOSIS' ENTERED AT 12:25:47 ON 03 AUG 2004

=> s multi-drug resistance or MDR or multidrug resistance
L12 55745 MULTI-DRUG RESISTANCE OR MDR OR MULTIDRUG RESISTANCE

=> s l12 and inhibit?
L13 19635 L12 AND INHIBIT?

=> s annexin I
L14 1405 ANNEXIN I

=> s l14 an dl13
MISSING OPERATOR L14 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l14 and l13
L15 17 L14 AND L13

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 17 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

ACCESSION NUMBER: 2004:185003 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix,LLC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004142889	A1	20040722	
APPLICATION INFO.:	US 2003-666898	A1	20030919	(10)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
LINE COUNT: 7754

L15 ANSWER 2 OF 17 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:165307 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S): Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126793	A1	20040701
APPLICATION INFO.:	US 2003-666885	A1	20030919 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 147
EXEMPLARY CLAIM: 1
LINE COUNT: 28979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 17 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition

comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:164872 USPATFULL
TITLE:	Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S):	Segal, Andrew H., Boston, MA, UNITED STATES Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S):	Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126357	A1	20040701
APPLICATION INFO.:	US 2003-666886	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
LINE COUNT:	39007

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:159413 USPATFULL
TITLE:	Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S):	Segal, Andrew H., Boston, MA, UNITED STATES Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S):	Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122217	A1	20040624
APPLICATION INFO.:	US 2003-666871	A1	20030919 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)

	US 2003-487407P 20030715 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS:	68
EXEMPLARY CLAIM:	1
LINE COUNT:	7880

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 17 USPATFULL on STN

TI Targets for therapeutic intervention identified in the mitochondrial proteome

AB Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences [SEQ ID NOS:1-3025] of polypeptides that comprise the human heart mitochondrial proteome are provided, using fractionated proteins derived from highly purified mitochondrial preparations, to identify previously unrecognized mitochondrial molecular components.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:133338 USPATFULL
TITLE:	Targets for therapeutic intervention identified in the mitochondrial proteome
INVENTOR(S):	Ghosh, Soumitra S., San Diego, CA, UNITED STATES Fahy, Eoin D., San Diego, CA, UNITED STATES Zhang, Bing, Spring, TX, UNITED STATES Gibson, Bradford W., Berkeley, CA, UNITED STATES Taylor, Steven W., San Diego, CA, UNITED STATES Glenn, Gary M., Encinitas, CA, UNITED STATES Warnock, Dale E., San Diego, CA, UNITED STATES Gaucher, Sara P., Castro Valley, CA, UNITED STATES
PATENT ASSIGNEE(S):	MitoKor Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation) The Buck Institute for Age Research, Novato, CA, UNITED STATES, 94948-0638 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004101874	A1	20040527	
APPLICATION INFO.:	US 2003-408765	A1	20030404	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412418P	20020920 (60)
	US 2002-389987P	20020617 (60)
	US 2002-372843P	20020412 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	5 Drawing Page(s)
LINE COUNT:	5998

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 17 USPATFULL on STN

TI Lectin compositions and methods for modulating an immune response to an antigen

AB The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic

acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:120097 USPATFULL
TITLE:	Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S):	Segal, Andrew H., Boston, MA, UNITED STATES Young, Elihu, Sharon, MA, UNITED STATES
PATENT ASSIGNEE(S):	Genitrix, LLC (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004091503	A1	20040513	
APPLICATION INFO.:	US 2003-645000	A1	20030820	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404823P	20020820 (60)
	US 2003-487407P	20030715 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS:	78
EXEMPLARY CLAIM:	1
LINE COUNT:	7933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 17 USPATFULL on STN

TI Molecular toxicology modeling

AB The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:94708 USPATFULL
TITLE:	Molecular toxicology modeling
INVENTOR(S):	Mendrick, Donna, Gaithersburg, MD, UNITED STATES Porter, Mark, Gaithersburg, MD, UNITED STATES Johnson, Kory, Gaithersburg, MD, UNITED STATES Higgs, Brandon, Gaithersburg, MD, UNITED STATES Castle, Arthur, Gaithersburg, MD, UNITED STATES Elashoff, Michael, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072160	A1	20040415	
APPLICATION INFO.:	US 2002-152319	A1	20020522	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292335P	20010522 (60)
	US 2001-297523P	20010613 (60)
	US 2001-298925P	20010619 (60)
	US 2001-303810P	20010710 (60)

	US 2001-303807P	20010710 (60)
	US 2001-303808P	20010710 (60)
	US 2001-315047P	20010828 (60)
	US 2001-324928P	20010927 (60)
	US 2001-330867P	20011101 (60)
	US 2001-330462P	20011022 (60)
	US 2001-331805P	20011121 (60)
	US 2001-336144P	20011206 (60)
	US 2001-340873P	20011219 (60)
	US 2002-357843P	20020221 (60)
	US 2002-357842P	20020221 (60)
	US 2002-357844P	20020221 (60)
	US 2002-364134P	20020315 (60)
	US 2002-370206P	20020408 (60)
	US 2002-370247P	20020408 (60)
	US 2002-370144P	20020408 (60)
	US 2002-371679P	20020412 (60)
	US 2002-372794P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 27909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 17 USPATFULL on STN
TI Lectin compositions and methods for modulating an immune response to an antigen
AB The present invention relates to a fusion polypeptide comprising at least about 10 contiguous amino acid residues of an influenza virus hemagglutinin and at least about 5 contiguous amino acids of a naturally occurring GM-CSF molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:51725 USPATFULL
TITLE: Lectin compositions and methods for modulating an immune response to an antigen
INVENTOR(S): Segal, Andrew, Boston, MA, UNITED STATES
Young, Eli, Sharon, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004039156	A1	20040226	
APPLICATION INFO.:	US 2002-224661	A1	20020820	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 7091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 9 OF 17 USPATFULL on STN
TI Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
AB A method of diagnosing a disease that includes obtaining experimental data on gene selections. The gene selection functions to characterize a cancer when the expression of that gene selection is compared to the identical selection from a noncancerous cell or a different type of cancer cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic

agent. The invention also includes the use of a gene selection for diagnosing a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:12636 USPATFULL
TITLE:	Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
INVENTOR(S):	Khan, Javed, Derwood, MD, UNITED STATES Ringner, Markus, Lund, SWEDEN Peterson, Carsten, Lund, SWEDEN Meltzer, Paul, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009154	A1	20040115
APPLICATION INFO.:	US 2002-159563	A1	20020531 (10)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-133937, filed on 25 Apr 2002, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, 3200 IDS CENTER, 80 SOUTH EIGHTH STREET, MINNEAPOLIS, MN, 55402-0903
NUMBER OF CLAIMS:	101
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Page(s)
LINE COUNT:	3943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 10 OF 17 USPATFULL on STN

TI Expression profile of prostate cancer

AB The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:250950 USPATFULL
TITLE:	Expression profile of prostate cancer
INVENTOR(S):	Chinnaiyan, Arul M., Plymouth, MI, UNITED STATES Rubin, Mark A., Ann Arbor, MI, UNITED STATES Sreekumar, Arun, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S):	The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175736	A1	20030918
APPLICATION INFO.:	US 2002-210120	A1	20020801 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309581P	20010802 (60)
	US 2001-334468P	20011115 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Tanya A. Arenson, MELDEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105
NUMBER OF CLAIMS:	101
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	129 Drawing Page(s)

LINE COUNT: 11938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 11 OF 17 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:194491 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134302	A1	20030717
APPLICATION INFO.:	US 2002-210985	A1	20020801 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 9810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 12 OF 17 USPATFULL on STN
TI Libraries of expressible gene sequences
AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as affinity purification tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:106252 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES

PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073163	A1	20030417
APPLICATION INFO.:	US 2001-3021	A1	20011114 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 9813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 13 OF 17 USPATFULL on STN
TI Early stage multipotential stem cells in colonies of bone marrow stromal cells
AB Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:301221 USPATFULL
TITLE: Early stage multipotential stem cells in colonies of bone marrow stromal cells
INVENTOR(S): Prockop, Darwin J., New Orleans, LA, UNITED STATES
Colter, David C., Philadelphia, PA, UNITED STATES
Sekiya, Ichiro, New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002168765	A1	20021114
APPLICATION INFO.:	US 2001-816182	A1	20010323 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 Market Street, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 14 OF 17 USPATFULL on STN
TI Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction

AB The invention relates to protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction. Using overlapping hexapeptides that encode for the entire amino acid sequences of the linker domains of human P-glycoprotein gene 1 and 3 (HP-gp1 and HP-gp3), a direct and specific binding between P-gp1 and 3 linker domains and intracellular proteins was demonstrated. Three different stretches (.sup.617EKGIYFKLVTM.sup.627, .sup.658SRSSLIRKRSTRRSVRGSQA.sup.677 and .sup.694PVSFWRIMKLNLT.sup.706 for P-gp1 and .sup.618LMKKEGVYFKLVNM.sup.631, .sup.64KAATRMAPNGWKSRLFRHSTQKNLKNS.sup.674 and .sup.695PVSFLKVLKLNKT.sup.677 for P-gp3) in linker domains bound to proteins with apparent molecular masses of .about.80 kDa, 57 kDa and 30 kDa. The binding of the 57 kDa protein was further characterized. Purification and partial N-terminal amino acid sequencing of the 57 kDa protein showed that it encodes the N-terminal amino acids of alpha and beta-tubulins. The method of the present invention was further validated with Annexin. The present invention thus demonstrates a novel concept whereby the interactions between two proteins are mediated by strings of few amino acids with high and repulsive binding energies, enabling the identification of high-affinity binding sites between any interacting proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:258778 USPATFULL
TITLE:	Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
INVENTOR(S):	Georges, Elias, Laval, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142348	A1	20021003
APPLICATION INFO.:	US 2001-10310	A1	20011113 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-CA587, filed on 12 May 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-134259P	19990514 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	16 Drawing Page(s)
LINE COUNT:	2044

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 15 OF 17 USPATFULL on STN

TI Taxol resistance associated gene

AB A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 ("TRAG-3"). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:64018 USPATFULL
TITLE:	Taxol resistance associated gene
INVENTOR(S):	Seiden, Michael V., Wayland, MA, United States Duan, Zhenfeng, Cambridge, MA, United States Feller, Aynn, Somerville, MA, United States
PATENT ASSIGNEE(S):	The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6362321	B1	20020326	
APPLICATION INFO.:	US 1999-277303		19990326	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79771P	19980327 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Harris, Alana M.
LEGAL REPRESENTATIVE: Fish & Richardson, P.C.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 16 OF 17 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature marrow stromal cells .
AN 2003-328406 [31] WPIDS
AB US2002168765 A UPAB: 20030516
NOVELTY - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC), is new. The cells within (I) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and annexin II (lipocortin 2).

DETAILED DESCRIPTION - A population (I) of small and rapidly self-renewing stem (RS) cells or a population (II) of large, more mature marrow stromal cells (mMSC) express one or more polypeptides such as vascular endothelial growth factor (VEGF) receptor-2 (FLK-1), TRK (an NGF receptor), transferrin receptor, and annexin II (lipocortin 2). The cells within (II) express one or more polypeptides such as STRO-1, platelet-derived growth factor (PDGF) receptor, epidermal growth factor (EGF) receptor, CD10 and CD147.

INDEPENDENT CLAIMS are also included for the following:

(1) Distinguishing a population of small and rapidly self-RS cells from a population of large mMSC, by assessing whether at least 29 polypeptides are expressed in the cells in the RS cell population but are not expressed in the mMSC population, and further at least 9 polypeptides are expressed in the population of MSC, but are not expressed in the population of RS cells, where the RS cells are 7 microns in diameter and the cells within the MSC cell population are 15-50 microns in diameter; and

(2) A population of small and rapidly RS cells and mMSC identified by the above method.

ACTIVITY - None given.

MECHANISM OF ACTION - Cell and gene therapy.

No supporting data is given.

USE - The method is useful for distinguishing a population of small and rapidly self-RS cells from a population of large mMSC (claimed). The two classes of bone marrow stem cells, small rapidly self-renewing stem cells and large more mature marrow stromal cells are useful in cell and gene therapy.

Dwg.0/4

ACCESSION NUMBER: 2003-328406 [31] WPIDS
DOC. NO. CPI: C2003-085353
TITLE: Population of cells useful in cell and gene therapy comprise two classes of bone marrow stem cells, small and rapidly self-renewing stem cells, and large more mature

marrow stromal cells .

DERWENT CLASS: B04 D16
INVENTOR(S): COLTER, D C; PROCKOP, D J; SEKIYA, I
PATENT ASSIGNEE(S): (COLT-I) COLTER D C; (PROC-I) PROCKOP D J; (SEKI-I) SEKIYA I
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2002168765	A1	20021114	(200331)*		11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2002168765	A1	US 2001-816182	20010323

PRIORITY APPLN. INFO: US 2001-816182 20010323

L15 ANSWER 17 OF 17 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Modulating or assessing **multidrug resistance** related to annexin proteins.
AN 1999-337419 [28] WPIDS
AB WO 9921980 A UPAB: 19990719
NOVELTY - Isolated nucleic acid (I) encoding an annexin family member (II), i.e. a member of the **MDR** (**multidrug resistance**) gene family, for assessing or modulating **MDR** in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for detecting and assessing annexin-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;

(2) kits for this method;

(3) recombinant vector for modulating, **inhibiting** and/or increasing annexin-based **MDR** in a cell, containing (I) linked to a promoter;

(4) cells containing this vector;

(5) a method for identifying compounds that affect annexin-based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing annexin-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;

(7) pharmaceutical composition for reducing **MDR** comprising annexin-based **MDR**-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, annexin-based **MDR** in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that **inhibits** (II), are used to prevent **MDR** in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with **MDR**, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.
Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing **multidrug resistance** related to annexin proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9896174	A Based on	WO 9921980
EP 1025225	A1 Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  May 12   EXTEND option available in structure searching
 NEWS  4  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS  6  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28   Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28   ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                   and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS 10  Jul 30   BEILSTEIN on STN workshop to be held August 24 in conjunction
                   with the 228th ACS National Meeting
 NEWS 11  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS 12  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS 13  AUG 02   STN User Update to be held August 22 in conjunction with the
                   228th ACS National Meeting
 NEWS 14  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:15:14 ON 03 AUG 2004

=> file medline, biosis, wpids, fsta, embase, dgene, jicst, japio, uspatful, hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    0.21        0.21

FILE 'MEDLINE' ENTERED AT 13:15:44 ON 03 AUG 2004

FILE 'BIOSIS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'EMBASE' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JICST-EPLUS' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 13:15:44 ON 03 AUG 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'USPATFULL' ENTERED AT 13:15:44 ON 03 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 13:15:44 ON 03 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s MDR adj decrease
L1             0 MDR ADJ DECREASE

=> s MDR adj inhibit?
L2             0 MDR ADJ INHIBIT?

=> s multidrug resistance and inhibit
L3          3517 MULTIDRUG RESISTANCE AND INHIBIT

=> s l3 and compound
L4          1433 L3 AND COMPOUND

=> s l4 and annexin
L5            78 L4 AND ANNEXIN

=> s l5 and annexin
L6            78 L5 AND ANNEXIN

=> s l6 and annexin I
L7             5 L6 AND ANNEXIN I

=> s (multidrug resistance inhibition) with (annexin I)
MISSING OPERATOR HIBITION) WITH
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (multidrug resistance inhibition) and (annexin I)
L8             0 (MULTIDRUG RESISTANCE INHIBITION) AND (ANNEXIN I)

=> s (multidrug resistance inhibition) near(annexin I)
MISSING OPERATOR HIBITION) NEAR
```

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (multidrug resistance inhibition) adj2 (annexin I)
MISSING OPERATOR HIBITION) ADJ2
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s multidrug resistance inhibition
L9 65 MULTIDRUG RESISTANCE INHIBITION

=> s l9 and annexin
L10 0 L9 AND ANNEXIN

=> s l9 and annexin I
L11 0 L9 AND ANNEXIN I

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  May 12   EXTEND option available in structure searching
 NEWS  4  May 12   Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27   New UPM (Update Code Maximum) field for more efficient patent
                   SDIs in CAplus
 NEWS  6  May 27   CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28   Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28   ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                   and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12   BEILSTEIN enhanced with new display and select options,
                   resulting in a closer connection to BABS
 NEWS 10  Jul 30   BEILSTEIN on STN workshop to be held August 24 in conjunction
                   with the 228th ACS National Meeting
 NEWS 11  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                   fields
 NEWS 12  AUG 02   CAplus and CA patent records enhanced with European and Japan
                   Patent Office Classifications
 NEWS 13  AUG 02   STN User Update to be held August 22 in conjunction with the
                   228th ACS National Meeting
 NEWS 14  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:56:22 ON 03 AUG 2004

=> file medline, biosis, embase, dgene, wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 14:56:36 ON 03 AUG 2004

FILE 'BIOSIS' ENTERED AT 14:56:36 ON 03 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 14:56:36 ON 03 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 14:56:36 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 14:56:36 ON 03 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

=> s lipocortin I
L1 549 LIPOCORTIN I

=> s annexin with MDR
L2 1 ANNEXIN WITH MDR

=> s l1 and MDR
L3 1 L1 AND MDR

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Modulating or assessing multidrug resistance related to annexin proteins.
AN 1999-337419 [28] WPIDS
AB WO 9921980 A UPAB: 19990719
NOVELTY - Isolated nucleic acid (I) encoding an annexin family member (II), i.e. a member of the MDR (multidrug resistance) gene family, for assessing or modulating MDR in a cell, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method for detecting and assessing **annexin**-based **MDR** by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an annexin, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;
(2) kits for this method;
(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based **MDR** in a cell, containing (I) linked to a promoter;
(4) cells containing this vector;
(5) a method for identifying compounds that affect **annexin** -based **MDR** by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;
(6) a method of reducing **annexin**-based **MDR** by administering a nucleic acid, (dominant negative) mutant of annexin, antibody to annexin, peptide or small molecule;
(7) pharmaceutical composition for reducing MDR comprising **annexin**-based **MDR**-affecting compound and a carrier; and
(8) methods for diagnosing presence of, or predisposition to, **annexin**-based **MDR** in a patient or pathogen.
ACTIVITY - Antitumor; antifungal.
MECHANISM OF ACTION - None given.
USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be

used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.
Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing multidrug resistance related to annexin proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9896174	A	Based on	WO 9921980
EP 1025225	A1	Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI INCREASED TYROSINE PHOSPHORYLATION OF **LIPOCORTIN I** IN MULTIDRUG RESISTANT SARCOMA 180 CELLS.
ACCESSION NUMBER: 1991:379014 BIOSIS
DOCUMENT NUMBER: PREV199141051404; BR41:51404
TITLE: INCREASED TYROSINE PHOSPHORYLATION OF **LIPOCORTIN I** IN MULTIDRUG RESISTANT SARCOMA 180 CELLS.
AUTHOR(S): BHUSHAN A [Reprint author]; TRITTON T R
CORPORATE SOURCE: DEP PHARMACOL AND VT REGIONAL CANCER CENT, UNIV VT, BURLINGTON, VT 05405, USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (1991) Vol. 32, pp. 362.
Meeting Info.: PROCEEDINGS OF THE 82ND ANNUAL MEETING OF

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, HOUSTON, TEXAS, USA, MAY 15-18, 1991. PROC AM ASSOC CANCER RES ANNU MEET.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
FILE SEGMENT: BR
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 17 Aug 1991
Last Updated on STN: 17 Aug 1991

Refine Search

Search Results -

Terms	Documents
annexin 1 and L11	671

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, August 03, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L12	annexin 1 and L11	671	L12
L11	sacroma cells and L10	159	L11
L10	lipocortin and L9	132	L10
L9	tyrosine phosphorylation	35781	L9
L8	Annexin I and l7	90967	L8
L7	L6 and MDR inhibition	107982	L7
L6	lipocrotin I	1167818	L6
L5	L4 and annexin	7	L5
L4	l2 and MDR	16	L4
L3	Tritton.in.	13	L3
L2	cole.in.	4788	L2
L1	bhushan.in	0	L1

END OF SEARCH HISTORY

h e b b cg b e e ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 6063621 A

L5: Entry 1 of 7 File: USPT May 16, 2000

US-PAT-NO: 6063621
DOCUMENT-IDENTIFIER: US 6063621 A
**** See image for Certificate of Correction ****

TITLE: Antibodies to a multidrug resistance protein

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/330; 424/155.1, 530/388.8

Full | Title | Citation | Front | Review | Classification | Date | Reference | ... | Claims | KWIC | Draw De

☐ 2. Document ID: US 6025473 A

L5: Entry 2 of 7 File: USPT Feb 15, 2000

US-PAT-NO: 6025473
DOCUMENT-IDENTIFIER: US 6025473 A
**** See image for Certificate of Correction ****

TITLE: Multidrug resistance proteins

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P. C.	Kingston			CA

US-CL-CURRENT: 530/350; 435/183, 530/300, 530/395, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | ... | Claims | KWIC | Draw De

h e b b g e e e f e ef b e

☐ 3. Document ID: US 6001563 A

L5: Entry 3 of 7 File: USPT Dec 14, 1999

US-PAT-NO: 6001563
DOCUMENT-IDENTIFIER: US 6001563 A
**** See image for Certificate of Correction ****

TITLE: Methods for identifying chemosensitizers

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P.C.	Kingston			CA

US-CL-CURRENT: 435/6; 424/9.1, 435/29, 435/325, 435/4, 800/13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 4. Document ID: US 5891724 A

L5: Entry 4 of 7 File: USPT Apr 6, 1999

US-PAT-NO: 5891724
DOCUMENT-IDENTIFIER: US 5891724 A
**** See image for Certificate of Correction ****

TITLE: Methods for conferring multidrug resistance on a cell

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/375; 435/320.1, 435/325, 435/367, 435/456, 435/6, 435/69.1, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 5. Document ID: US 5882875 A

L5: Entry 5 of 7 File: USPT Mar 16, 1999

US-PAT-NO: 5882875
DOCUMENT-IDENTIFIER: US 5882875 A
**** See image for Certificate of Correction ****

h e b b g e e e f e ef b e

TITLE: Methods for identifying multidrug resistant tumor cells

DATE-ISSUED: March 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P. C.	Kingston			CA

US-CL-CURRENT: 435/7.23; 424/155.1, 530/388.8

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | Claims | KWMC | Draw De

---

☐ 6. Document ID: US 5766880 A

L5: Entry 6 of 7 File: USPT Jun 16, 1998

US-PAT-NO: 5766880
DOCUMENT-IDENTIFIER: US 5766880 A

TITLE: Isolated nucleic acid molecules encoding multidrug resistance proteins

DATE-ISSUED: June 16, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P.C.	Kingston			CA

US-CL-CURRENT: 435/69.1; 435/243, 435/320.1, 435/366, 435/372, 536/23.5, 536/24.31

Full | Title | Citation | Front | Review | Classification | Date | Reference | [illegible] | Claims | KWMC | Draw De

---

☐ 7. Document ID: US 5489519 A

L5: Entry 7 of 7 File: USPT Feb 6, 1996

US-PAT-NO: 5489519
DOCUMENT-IDENTIFIER: US 5489519 A
**** See image for Certificate of Correction ****

TITLE: Multidrug resistance protein

DATE-ISSUED: February 6, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deeley; Roger G.	Kingston			CA
Cole; Susan P. C.	Kingston			CA

h e b b g e e e f e ef b e

US-CL-CURRENT: 435/69.1; 435/320.1, 435/372, 435/69.7, 536/23.5, 536/24.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L4 and annexin	7

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e ef b e

Refine Search

Search Results -

Terms	Documents
L23 and L26	122

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L27

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, August 03, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L27	l23 and L26	122	L27
L26	george.in.	145012	L26
L25	georges.in.	145012	L25
L24	L23 and georges	764	L24
L23	wang.in.	12989	L23
L22	L21 and annexin	463	L22
L21	l20 and dominant negative mutant	498124	L21
L20	l17 and antibody	763	L20
L19	MDR adj2 annexin I	1167818	L19
L18	MDR adj1 inhibit	0	L18
L17	L16 and l14	1168	L17
L16	multidrug resistance with inhibit	5051	L16
L15	l7 and L14	372	L15
L14	annexin I and L13	1670	L14

h e b b cg b e e ch

L13	inhibition and L12	1206	L13
L12	multidrug resistance with annexin	1661	L12
L11	l9 and L10	77766	L11
L10	(annexin based multidrug resistance)	1583919	L10
L9	Annexin inhibition	107228	L9
L8	l1 and L7	1	L8
L7	L6 and l5	372	L7
L6	l2 and annexin	373	L6
L5	L4 and annexin I	1167822	L5
L4	l2 and inhibit	72589	L4
L3	l1 and L2	1	L3
L2	multidrug resistance	750917	L2
L1	6362321.pn.	1	L1

END OF SEARCH HISTORY

h e b b cg b e e ch